Actuate Therapeutics, Inc. ACTU

ACTU Company Overview

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers and other difficult-to-treat diseases. The company’s core scientific platform centers on glycogen synthase kinase-3 (GSK-3) inhibition, with its lead product candidate, elraglusib (formerly known as 9-ING-41), being evaluated across multiple oncology indications. Actuate operates within the biotechnology and oncology drug development industries, with an emphasis on combination therapies designed to enhance the effectiveness of existing cancer treatments.

The company’s primary revenue and enterprise value drivers are tied to the clinical advancement, licensing potential, and commercialization prospects of its drug candidates, particularly elraglusib. Actuate has focused on cancers with high unmet medical need, including pancreatic cancer, glioblastoma, and other advanced solid tumors. The company was founded in 2015 and evolved from an early-stage oncology research organization into a publicly traded clinical-stage biotechnology company following its Nasdaq listing under the ticker ACTU. Its strategic positioning is based on differentiated GSK-3 inhibition technology and the potential applicability of its platform across multiple tumor types and therapeutic combinations.